Tessera Therapeutics
Founded Year
2018Stage
Grant | AliveTotal Raised
$530MMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-18 points in the past 30 days
About Tessera Therapeutics
Tessera Therapeutics focuses on Gene Writing, a genome engineering technology within the biotech sector. The company develops a platform that enables alterations to the human genome to address diseases. Tessera Therapeutics aims to address medical needs with therapies, using tissue-targeted non-viral delivery methods to ensure changes are made where needed. It was founded in 2018 and is based in Cambridge, Massachusetts.
Loading...
Loading...
Expert Collections containing Tessera Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Tessera Therapeutics is included in 2 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,270 items
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Latest Tessera Therapeutics News
Dec 19, 2024
December 19, 2024 Tessera Therapeuti cs , a Somerville, MA-based biotechnology company providing a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, received an investment from Bill & Melinda Gates Foundation. The funding included an initial investment, with potential total investment of up to $50M. The company intends to use the funds to advance a SCD treatment and further its objectives to develop genetic medicines that are accessible globally. Led by CEO Michael Severino, Tessera is developing Gene Writers™ for SCD designed to enable a true correction of the sickle mutation to wild-type with one-time intravenous administration in vivo, without the need for complex stem cell mobilization or toxic chemotherapy conditioning. Critical in enabling in vivo therapies, the company is leveraging its proprietary non-viral delivery platform to develop lipid nanoparticles targeting delivery of Gene Writers to long-term hematopoietic stem cells.
Tessera Therapeutics Frequently Asked Questions (FAQ)
When was Tessera Therapeutics founded?
Tessera Therapeutics was founded in 2018.
Where is Tessera Therapeutics's headquarters?
Tessera Therapeutics's headquarters is located at 55 Cambridge Parkway, Cambridge.
What is Tessera Therapeutics's latest funding round?
Tessera Therapeutics's latest funding round is Grant.
How much did Tessera Therapeutics raise?
Tessera Therapeutics raised a total of $530M.
Who are the investors of Tessera Therapeutics?
Investors of Tessera Therapeutics include Bill & Melinda Gates Foundation, SoftBank, Altitude Life Science Ventures, Alaska Permanent Fund, Artis Ventures and 12 more.
Loading...
Loading...